@article{MAKHILLJAVA20109102230, title = {Investigation on Efficacy of a Commercial Vaccine for Treatment of Leptospirosis in Cattle}, journal = {Journal of Animal and Veterinary Advances}, volume = {9}, number = {10}, pages = {1531-1533}, year = {2010}, issn = {1680-5593}, doi = {javaa.2010.1531.1533}, url = {https://makhillpublications.co/view-article.php?issn=1680-5593&doi=javaa.2010.1531.1533}, author = {Sedat,Serkal and}, keywords = {treatment,prognosis,leptospirosis,Lepto Shield 5®,Cattle,vaccination}, abstract = {The aim of this study was to determinate leptospirosis in cattle and to investigate efficacy of a commercial vaccine in treatment of leptospirosis. Upon observing leptosipirosis specific clinical signs including haematuria and mucosal icterus in 2 heifers and mouse fleshes on the surface of the water reserve of the farm, the clinicians tentatively diagnosed the diseased heifers as leptosiprosis. In addition, 9 heifers had general clinical signs including fever, apathy and tachypnea. Blood samples were collected from 41 heifers kept in the farm, including those exhibiting specific and non-specific clinical signs. All clinically diseased heifers were seropositive for leptosirosis confirmed by Microagglutination Test (MAT). The antibody titers were 1/100 or above in 11 out of 41 heifers (26.8%). All 41 heifers were vaccinated with a specific commercial vaccine (Lepto Shield 5®) developed against leptospirosis. At the forth day of vaccination, one of the diseased heifers died of acute leptospirosis while the others clinically recovered 8 days after vaccination and none of the seropositive heifers showed any clinical signs of the disease. No side effects were observed within a month following vaccination. The results of the present study suggest that Lepto Shield 5® is effective not only for protection but also for treatment of leptospirosis in cattle.} }